[The impact of CD34(+) cells and T cells subsets in grafts on prognosis of HLA-identical sibling allogeneic peripheral blood stem cell transplantation]
- PMID: 19176036
[The impact of CD34(+) cells and T cells subsets in grafts on prognosis of HLA-identical sibling allogeneic peripheral blood stem cell transplantation]
Abstract
Objective: To study the influence of CD34(+) and T cells doses in grafts on prognosis after HLA-identical sibling allogeneic peripheral blood stem cell transplantation (allo-PBSCT).
Methods: Sixty-five patients received HLA-identical sibling allo-PBSCT were studied. The numbers of CD34(+), CD3(+), CD3(+)CD4(+) and CD3(+)CD8(+) T cells in the grafts were measured by fluorescence-activated cell sorting (FACS). The doses of MNC, and the above cells in grafts were calculated as per kilogram of recipient's body weight. The patients were divided into high-dose (HD) or low-dose (LD) groups according to median dose of those cells, respectively. Hematopoiesis reconstitution, incidence of graft versus host disease (GVHD), transplant-related mortality (TRM), overall survival (OS), and disease-free survival (DFS) were analyzed.
Results: HD CD34(+) cells significantly accelerated neutrophil and platelet reconstitution (P < 0.05). There seems a trend toward increasing incidence of grade II approximately IV acute GVHD (aGVHD) in HD CD3(+)CD4(+) and CD3(+)CD8(+) T cells groups compared with those LD groups (P = 0.089 and 0.098, respectively). The TRM rates were significantly higher and OS rates were significantly in HD CD3(+)CD4(+) and CD3(+)CD8(+) T cells groups than in LD groups, respectively (both P < 0.05). Multivariate analyses showed that CD3(+)CD4(+) and CD3(+)CD8(+) T cells doses in grafts were significant risk factors for TRM \[relative risk (RR) were 13.12 and 25.90, respectively, both P < 0.05\] and for OS (RR were 3.71 and 3.01, respectively, both P < 0.05). The DFS rate was significantly lower in HD CD3(+)CD4(+) T cells groups than in LD groups (P < 0.05). Multivariate analyses showed that CD3(+)CD4(+) cells dose in grafts was a significant risk factor for DFS (RR = 6.91, P = 0.011).
Conclusions: High dose CD34(+) cells in grafts significantly accelerate hematopoietic reconstitution. Transfusion of high doses CD3(+)CD4(+) and CD3(+)CD8(+) cells increases TRM, but decrease OS or DFS.
Similar articles
-
Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children.Biol Blood Marrow Transplant. 2010 Oct;16(10):1388-401. doi: 10.1016/j.bbmt.2010.04.001. Epub 2010 Apr 9. Biol Blood Marrow Transplant. 2010. PMID: 20382248
-
Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT.Bone Marrow Transplant. 1998 Sep;22(6):519-25. doi: 10.1038/sj.bmt.1701386. Bone Marrow Transplant. 1998. PMID: 9758337
-
A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold?Bone Marrow Transplant. 2000 Sep;26(5):489-96. doi: 10.1038/sj.bmt.1702542. Bone Marrow Transplant. 2000. PMID: 11019837 Clinical Trial.
-
Negative depletion of CD3(+) and TcRαβ(+) T cells.Curr Opin Hematol. 2012 Nov;19(6):434-9. doi: 10.1097/MOH.0b013e3283582340. Curr Opin Hematol. 2012. PMID: 22914586 Review.
-
CD34 cell dose and chronic graft-versus-host disease after human leukocyte antigen-matched sibling hematopoietic stem cell transplantation.Leuk Lymphoma. 2004 Jan;45(1):27-34. doi: 10.1080/1042819031000151103. Leuk Lymphoma. 2004. PMID: 15061194 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials